We use cookies on our site to analyze traffic, enhance your experience, and provide you with tailored content.

For more information visit our privacy policy.

New Candidates Sample Clauses

New Candidates. Candidates for a faculty position will, whenever possible, be interviewed by the members of the faculty in the area in which they are being considered.
Sample 1
New Candidates. (a) During the Research Term, a Party will propose targets by way of notice in writing to the other Party including sufficient information with respect to the scientific and commercial potential of the target (each a “Target Notice”) so that the Parties can work on constructs for radiopharmaceutical products combining DARPin Technology and TAT Technology using 212Pb or using or combining (whether with DARPin Technology or TAT Technology) an Alternative Technology proposed by a Party under a MTA as set forth below. Molecular Partners may, but is not required to at this stage, indicate in the Target Notice whether the target is a Restricted Target. (b) With respect to each target proposed by a Party under a Target Notice and within [***] of the Target Notice: (i) the other Party (the “Rejecting Party”) may notify the JSC in writing that it refuses to work on such target (the “Rejected Target”) and in doing so shall provide a reasonable justification for such refusal which may only be based on the following criteria, provided that if evidence is required by the JSC, a Rejecting Party will provide it and may do so, if it deems it necessary via a third party under terms reasonably acceptable to each Party to preserve confidentiality: (1) such work is conflicting with, and would lead to a potential breach of, then current binding agreement(s) between the Rejecting Party and a Third Party; (2) the Rejecting Party can demonstrate that it has a previously established and still ongoing internal program on such target; or (3) the Rejecting Party considers, on the basis of a reasonable and objective scientific and commercial assessment of the target proposal that such targets are unlikely to be successful. The JSC shall be convened by the Collaboration Coordinators to discuss the above. (ii) If neither Party sends the notice referenced in 2.2(b)(i), OMT shall promptly indicate in writing to Molecular Partners whether OMT intends to work on such target: (1) under the present agreement or under the RDC Agreement provided that OMT shall not be entitled to opt for such work to be undertaken under the RDC Agreement: (a) if the target is already designated as a Restricted Target; or (b) without prejudice to OMT’s rights of Opt-In under this Agreement, where Molecular Partners has performed validation of a target prior to Molecular Partners issuing a Target Notice for that target, and Molecular Partners notifies OMT that Molecular Partners does not agree to that target being...
Sample 1

Related to New Candidates

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

Most Referenced Clauses

Most Referenced Definitions